Eagle Asset Management Inc. Has $49.01 Million Stock Holdings in NuVasive, Inc. (NASDAQ:NUVA)

Eagle Asset Management Inc. boosted its stake in NuVasive, Inc. (NASDAQ:NUVA) by 36.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 773,271 shares of the medical device company’s stock after buying an additional 205,052 shares during the period. Eagle Asset Management Inc. owned approximately 1.49% of NuVasive worth $49,009,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in NUVA. Retirement Systems of Alabama grew its stake in NuVasive by 0.4% in the 2nd quarter. Retirement Systems of Alabama now owns 67,488 shares of the medical device company’s stock valued at $3,951,000 after buying an additional 270 shares during the last quarter. Zions Bancorporation N.A. grew its stake in NuVasive by 6.1% in the 2nd quarter. Zions Bancorporation N.A. now owns 3,280 shares of the medical device company’s stock valued at $192,000 after buying an additional 190 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in NuVasive by 1.4% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 20,886 shares of the medical device company’s stock valued at $1,223,000 after buying an additional 295 shares during the last quarter. Cerebellum GP LLC acquired a new position in NuVasive in the 2nd quarter valued at about $354,000. Finally, Westside Investment Management Inc. acquired a new position in NuVasive in the 2nd quarter valued at about $87,000. Institutional investors and hedge funds own 99.91% of the company’s stock.

A number of brokerages recently commented on NUVA. Royal Bank of Canada upped their price target on shares of NuVasive to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, September 24th. BidaskClub upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a research note on Tuesday, September 24th. BMO Capital Markets upped their price target on shares of NuVasive from $54.00 to $68.00 and gave the company a “market perform” rating in a research note on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of NuVasive in a research note on Thursday, August 8th. Finally, TheStreet upgraded shares of NuVasive from a “c+” rating to a “b” rating in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. NuVasive presently has an average rating of “Hold” and an average target price of $67.42.

Shares of NASDAQ:NUVA opened at $72.19 on Friday. The company’s 50 day moving average price is $66.10 and its two-hundred day moving average price is $62.20. NuVasive, Inc. has a 12-month low of $43.51 and a 12-month high of $73.00. The firm has a market cap of $3.69 billion, a PE ratio of 32.37, a PEG ratio of 2.73 and a beta of 1.18. The company has a quick ratio of 2.08, a current ratio of 3.68 and a debt-to-equity ratio of 0.79.

NuVasive (NASDAQ:NUVA) last announced its earnings results on Wednesday, October 30th. The medical device company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.06. NuVasive had a net margin of 4.15% and a return on equity of 14.93%. The firm had revenue of $290.80 million for the quarter, compared to analyst estimates of $283.75 million. During the same quarter in the prior year, the business posted $0.56 EPS. The business’s revenue was up 7.2% compared to the same quarter last year. On average, research analysts expect that NuVasive, Inc. will post 2.37 EPS for the current year.

NuVasive Profile

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Further Reading: What is the return on assets (ROA) ratio?

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.